Effects of tyrosine kinase inhibitors on rat isolated heart function and protein biomarkers indicative of toxicity

Journal of Pharmacological and Toxicological Methods

Volumn 68, Issue 1, 2013, Pages 150-159

  Henderson, Kimberly A ^a   Borders, R Brandon ^a   Ross, John B ^a   Huwar, Theresa B ^a   Travis, Calvin O ^a   Wood, Brandon J ^a   Ma, Zhenxu J ^a   Hong, S Peter ^a   Vinci, Thomas M ^a   Roche, Brian M ^a  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Biomarker; Contractility; Erlotinib; FCCP; Isolated heart; Isoproterenol; Rat; Sorafenib; Sunitinib; Verapamil

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; ERLOTINIB; INTERLEUKIN 6; ISOPRENALINE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG EFFECT; EX VIVO STUDY; FLOW RATE; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE CONTRACTILITY; ISOLATED HEART; NONHUMAN; PREDICTION; RAT;

BIOMARKER; CONTRACTILITY; ERLOTINIB; FCCP; ISOLATED HEART; ISOPROTERENOL; RAT; SORAFENIB; SUNITINIB; VERAPAMIL;

ANIMALS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; MYOCARDIAL CONTRACTION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; TOXICITY TESTS; VENTRICULAR FUNCTION, LEFT;

RATTUS;

EID: 84880046383     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.04.009     Document Type: Article

References (50)

1. Antman E.M., Tanasijevic M.J., Thompson B., Schactman M., McCabe C.H., Cannon C.P., et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. New England Journal of Medicine 1996, 335:1342-1349.
2. Arrode-Bruses G., Bruses J. Maternal immune activation by poly(I:C) induces expression of cytokines IL-1beta and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain. Journal of Neuroinflammation 2012, 9:83.
3. Aylin M., Emrah K., Omer D., Mehmet A., Yesilyurt A., Gelal A. Interactions between verapamil and digoxin in Langendorff-perfused rat hearts: The role of inhibition of P-glycoprotein in the heart. Basic & Clinical Pharmacology & Toxicology 2010, 107:847-852.
4. Azzawi M., Hasleton P.S., Kan S.W., Hillier V.F., Quigley A., Hutchinson I.V. Distribution of myocardial macrophages in the normal human heart. Journal of Anatomy 1997, 191:417-423.
5. Bell R.M., Mocanu M.M., Yellon D.M. Retrograde heart perfusion: The Langendorff technique of isolated heart perfusion. Journal of Molecular and Cellular Cardiology 2011, 50:940-950.
6. Broniscer A., Panetta J.C., O'Shaughnessy M., Fraga C., Bai F., Krasin M.J., et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clinical Cancer Research 2007, 13:1511-1515.
7. Chantawansri C., Huynh N., Yamanaka J., Garfinkel A., Lamp S., Inoue M., et al. Effect of metabolic inhibition on couplon behaviour in rabbit ventricular myocytes. Biophysical Journal 2008, 1(94(5)):1656-1666.
8. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. The Lancet 2007, 370:2011-2019.
9. Crespo O., Kang S., Daneman R., Lindstrom T., Ho P., Sobel R., et al. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. Journal of Clinical Immunology 2011, 31:1010-1020.
10. Cui G., Haoran W., Li R., Zhang L., Zhonghe L., Wang Y., et al. Polymorphism of tumor necrosis factor alpha (TNF-alpha) gene promoter, circulating TNF-alpha level, and cardiovascular risk factor for ischemic stroke. Journal of Neuroinflammation 2012, 9:235.
11. Ederhy S., Massard C., Dufaitre G., Balheda R., Meuleman C., Rocca C., et al. Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Investigational New Drugs 2012, 30:611-615.
12. Eisen T., Sternberg C.N., Robert C., Mulders P., Pyle L., Zbinden S., et al. Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. Journal of the National Cancer Institute 2012, 104:93-113.
13. Elliott W.J., Ram C.V.S. Calcium channel blockers. Journal of Clinical Hypertension 2011, 13:687-689.
14. Force T., Kolaja K. Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical and translation of preclinical models to clinical outcomes. Nature Reviews 2011, 10:111-126.
15. Gerhardt W., Ljungdahl L. Troponin T: A sensitive and specific diagnostic and prognostic marker of myocardial damage. Clinica Chimica Acta 1998, 272:47-57.
16. Gilles S., Zahler S., Welsch U., Sommerhoff C.P., Becker B.F. Release of TNFalpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. Cardiovascular Research 2003, 60:608-616.
17. Goodman V.L., Rock E.P., Dagher R., Ramchandani R.P., Abraham S., Gobburu J.V.S., et al. Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clinical Cancer Research 2007, 13:1367-1373.
18. Goodwin G.W., Taylor C.S., Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. Journal of Biological Chemistry 1998, 273:29530-29539.
19. Guo L., Dong Z., Guthrie H. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. Journal of Pharmacological and Toxicological Methods 2009, 60:130-151.
20. Gurevitch J., Frolkis I., Yuhas Y., Paz Y., Matsa M., Mohr R., et al. Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. Journal of the American College of Cardiology 1996, 28:247-252.
21. Hamada A., Sasaki J.-i, Saeki S., Iwamoto N., Inaba M., Ushijima S., et al. Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer. Pharmacogenomics 2012, 13:615-624.
22. Hamid T., Gu Y., Ortines R.V., Bhattacharya C., Wang G., Xuan Y.-T., et al. Divergent tumor necrosis factor receptor a related remodeling responses in heart failure: Role of nuclear factor kb and inflammatory activation. Circulation 2009, 119:1386-1397.
23. Hamlin R.L., Cruze C.A., Mittelstadt A., Kitjtawornrat A., Keene B.W., Roche B.M., et al. Sensitivity and specificity of isolated perfused guinea pig heart to test for drug-induced lengthening of QTc. Journal of Pharmacological and Toxicological Methods 2003, 49:15-23.
24. Haque R., Kan H., Finkel M. Effects of cytokines and nitric oxide on myocardial E-C coupling. Basic Research in Cardiology 1998, 93:86-94.
25. Hensley M.L., Schuchter L., Lindley C., Meropol N., Cohen G., Broder G., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. Journal of Clinical Oncology 1999, 17:3333-3355.
26. Herman E., Zhang J., Lipshulz S.E., Rifai N., Chadwick D., Takeda K., et al. Correlation between serum levels of cardiac troponin-T and the severity of chronic cardiomyopathy induced by doxorubicin. Journal of Clinical Oncology 1999, 17:2237-2243.
27. Inaba H., Rubnitz J.E., Coustan-Smith E., Li L., Furmanski B.D., Mascara G.P., et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. Journal of Clinical Oncology 2011, 29:3293-3300.
28. Kapadia S.R., Torre-Amione G., Birdsall H., Ma T., Mann D.L. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. The Journal of Clinical Investigation 1995, 96:1042-1052.
29. Kapadia S.R., Yakoob K., Nader S., Thomas J.D., Mann D.L., Griffin B.P. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. Journal of the American College of Cardiology 2000, 36:208-212.
30. Kiewe P., Hasmuller S., Kahlert S., Heinrigs M., Rack B., Marme A., et al. Phase I trial of the trifunctional anti-HER2 x - Anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clinical Cancer Research 2006, 12:3085-3091.
31. Laverty H.G., Benson C., Cartwright E.J., Cross M.J., Garland C., Hammond T., et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. British Journal of Pharmacology 2011, 163:675-693.
32. Lee J.H., Chung Y.-H., Kim J.A., Shim J.H., Lee D., Lee H.C., et al. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 2013, 119:136-142.
33. Lieu P., Fornari M., Ramos T., Hatcher A., Clements-Jewery H. Reduced antiarrhythmic efficacy of verapamil in isolated rat hearts in the presence of elevated extracellular calcium. Journal of Cardiovascular Pharmacology 2011, 57:455-462.
34. Lin J.-C., Liu C.-L., Lee J.-J., Liu T.-P., Ko W.-C., Huang Y.-C., et al. Sorafenib induces autophagy and suppresses activation of human macrophage. International Immunopharmacology 2013, 15:333-339.
35. Lopaschuk G., Saddik M. The relative contribution of glucose and fatty acids to ATP production in hearts reperfused following ischemia. Molecular and Cellular Biochemistry 1992, 116:111-116.
36. Lou H., Danelisen I., Singal P.K. Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. Journal of Molecular and Cellular Cardiology 2004, 36:683-690.
37. Menna P., Salvatorelli E., Minotti G. Cardiotoxicity of antitumor drugs. Chemical Research in Toxicology 2008, 21:978-989.
38. Mori Y., Kondo C., Tonomura Y., Torii M., Uehara T. Identification of potential genomic biomarkers for early detection of chemically induced cardiotoxicity in rats. Toxicology 2010, 271:36-44.
39. Motzer R., Hutson T., Tomczak P., Michaelson M., Bukowski R., Rixe O. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine 2007, 356:115-124.
40. Orphanos G., Ioannidis G., Ardavanis A. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncologica 2009, 48:964-970.
41. Osadchii O.E., Norton G.R., McKechnie R., Deftereos D., Woodiwiss A.J. Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic adrenoreceptor activation. American Journal of Physiology - Heart and Circulatory Physiology 2007, 292:H1898-H1905.
42. Palmieri E.A., Benincasa G., Di Rella F., Casaburi C., Monti M.G., De Simone G., et al. Differential expression of TNF alpha, IL-6, and IGF-1 by graded mechanical stress in normal rat myocardium. American Journal of Physiology - Heart and Circulatory Physiology 2002, 282:H926-H934.
43. Piccini J., Whellan D., Berridge B., Finkle J., Pettit S., Stockbridge N., et al. Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative. American Heart Journal 2009, 158:17-26.
44. Qian J.-Y., Guo L. Altered cytosolic Ca2+ dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants. Toxicology in Vitro 2010, 24:960-972.
45. Schultze A.E., Main B.W., Hall D.G., Hoffman W.P., Lee H.-Y.C., Ackermann B.L., et al. A comparison of mortality and cardiac biomarker response between three outbred stocks of Sprague Dawley rats treated with isoproterenol. Toxicologic Pathology 2011, 39:576-588.
46. Tokarska-Schlattner M., Zaugg M., da Silva R., Lucchinetti E., Schaub M.C., Wallimann T., et al. Acute toxicity of doxorubicin on isolated perfused heart: Response of kinases regulating energy supply. American Journal of Physiology - Heart and Circulatory Physiology 2005, 289:H37-H47.
47. Tolcher A., Appleman L., Shapiro G., Mita A., Cihon F., Mazzu A., et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemotherapy and Pharmacology 2011, 67:751-764.
48. Tsai S.-H., Chu S.-J., Hsu C.-W., Cheng S.-M., Yang S.-P. Use and interpretation of cardiac troponins in the ED. The American Journal of Emergency Medicine 2008, 26:331-341.
49. Watanabe T., Smith M.M., Robinson F.W., Kono T. Insulin action on glucose transport in cardiac muscle. Journal of Biological Chemistry 1984, 259:13117-13122.
50. Yang B., Papoian T. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: Approaches to narrow the gaps between preclinical safety evaluation and clinical outcome. Journal of Applied Toxicology 2012, 32:945-951.